Taiko Pharmaceutical Co., Ltd. (JP:4574)
:4574
Want to see JP:4574 full AI Analyst Report?
Top Page
Taiko Pharmaceutical Co., Ltd.
(4574)
Select Model
Select Model
Rating:66Neutral
Price Target:
¥285.00
▼(-6.56% Downside)
Action:Reiterated
Date:02/18/26
The score is driven primarily by improving financial fundamentals (profitability and cash flow recovery with materially lower leverage), supported by positive technical momentum. Valuation is broadly reasonable but not especially compelling given the modest dividend yield, and the recent history of earnings/cash-flow volatility remains a key risk.
Positive Factors
Balance-sheet improvement
Material debt reduction meaningfully improves financial flexibility and lowers refinancing and interest-rate risk. A stronger equity base and much lower leverage provide durable capacity to fund R&D, manufacturing or strategic moves without immediate external financing.
Negative Factors
Earnings volatility
Large swings in profitability across years show earnings are cyclical or execution-sensitive. This history raises risk that current profits are not yet structurally embedded, complicating forecasting and capital allocation and requiring sustained evidence of repeatable performance.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance-sheet improvement
Material debt reduction meaningfully improves financial flexibility and lowers refinancing and interest-rate risk. A stronger equity base and much lower leverage provide durable capacity to fund R&D, manufacturing or strategic moves without immediate external financing.
Read all positive factors
Taiko Pharmaceutical Co., Ltd. (4574) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥13.22B
Dividend YieldN/A
Average Volume (3M)93.84K
Price to Earnings (P/E)25.1
Beta (1Y)0.73
Revenue Growth1.62%
EPS Growth-25.43%
CountryJP
Employees214
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)8.23
Shares Outstanding50,636,900
10 Day Avg. Volume93,940
30 Day Avg. Volume93,840
Financial Highlights & Ratios
PEG Ratio6.05
Price to Book (P/B)1.76
Price to Sales (P/S)2.34
P/FCF Ratio28.62
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)12.9
Revenue Forecast (FY)¥6.75B
Taiko Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Taiko Pharmaceutical Co.,Ltd. operates primarily in the pharmaceutical sector and the field of infection prevention. The company manufactures and distributes various over-the-counter medications, including its well-known Seirogan and Seirogan Toi-...
How the Company Makes Money
Taiko Pharmaceutical generates revenue primarily by selling pharmaceutical products. Key revenue streams typically include prescription and/or over-the-counter (OTC) drug sales to wholesalers, pharmacies, hospitals, and other healthcare providers,...
Taiko Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
57
Neutral
Balance Sheet
72
Positive
Cash Flow
54
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.84B | 6.40B | 6.29B | 6.12B | 5.04B | 10.72B |
| Gross Profit | 3.31B | 3.48B | 3.67B | 2.58B | 1.08B | 2.75B |
| EBITDA | 893.00M | 724.00M | 882.00M | -2.85B | -2.34B | -4.01B |
| Net Income | 413.00M | 923.00M | 898.00M | -3.61B | -4.89B | -9.59B |
Balance Sheet | ||||||
| Total Assets | 11.68B | 12.27B | 12.91B | 13.22B | 15.05B | 22.54B |
| Cash, Cash Equivalents and Short-Term Investments | 4.14B | 4.26B | 4.53B | 5.48B | 3.50B | 6.10B |
| Total Debt | 1.32B | 816.00M | 2.03B | 3.25B | 3.81B | 4.77B |
| Total Liabilities | 3.73B | 3.75B | 4.95B | 6.48B | 7.00B | 9.72B |
| Stockholders Equity | 7.95B | 8.52B | 7.96B | 6.74B | 8.04B | 12.81B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 523.00M | 205.00M | -421.00M | -2.08B | -3.19B |
| Operating Cash Flow | 0.00 | 814.00M | 362.00M | -307.00M | -1.99B | -1.59B |
| Investing Cash Flow | 0.00 | 142.00M | -5.00M | 1.17B | 190.00M | -1.62B |
| Financing Cash Flow | 0.00 | -1.23B | -1.18B | 1.54B | -997.00M | 3.96B |
Taiko Pharmaceutical Co., Ltd. Technical Analysis
Neutral
305.00
Price Trends
276.04
Negative
285.47
Negative
289.43
Negative
Market Momentum
-2.65
Negative
49.35
Neutral
74.24
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4574, the sentiment is Neutral. The current price of 305 is above the 20-day moving average (MA) of 258.20, above the 50-day MA of 276.04, and above the 200-day MA of 289.43, indicating a neutral trend. The MACD of -2.65 indicates Negative momentum. The RSI at 49.35 is Neutral, neither overbought nor oversold. The STOCH value of 74.24 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4574.
Taiko Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
66 Neutral | ¥13.22B | 25.13 | ― | ― | 1.62% | -25.43% | |
63 Neutral | ¥8.77B | 14.02 | ― | 2.55% | -0.61% | 14.60% | |
53 Neutral | ¥8.92B | 39.26 | ― | 1.06% | 27.18% | 252.59% | |
52 Neutral | ¥18.26B | 8.74 | ― | 3.71% | 2.88% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | ¥15.56B | 36.14 | ― | 3.65% | 8.42% | 49.52% | |
50 Neutral | ¥5.49B | 28.72 | ― | 3.21% | 1.60% | -32.57% |
* Healthcare Sector Average
JP:4574
Taiko Pharmaceutical Co., Ltd.
264.00
-95.00
-26.46%
JP:2929
Pharma Foods International Co., Ltd.
537.00
-303.51
-36.11%
JP:4512
Wakamoto Pharmaceutical Co., Ltd.
257.00
-46.44
-15.31%
JP:4524
Morishita Jintan Co., Ltd.
2,151.00
91.09
4.42%
JP:4538
Fuso Pharmaceutical Industries,Ltd.
2,082.00
76.76
3.83%
JP:4539
Nippon Chemiphar Co., Ltd.
1,520.00
45.00
3.05%
Taiko Pharmaceutical Co., Ltd. Corporate Events
Taiko Pharmaceutical Releases Q1 FY2026 Results and Full-Year Forecast
May 14, 2026
Taiko Pharmaceutical Co., Ltd. has released its consolidated financial results for the first quarter of the fiscal year ending December 31, 2026, providing an overview of its performance for the three-month period. The company also outlined perfor...
Taiko Pharmaceutical Swings to Q1 Loss but Maintains 2026 Profit and Dividend Outlook
May 14, 2026
Taiko Pharmaceutical reported a sharp downturn for the first quarter ended March 31, 2026, with net sales falling 20.4% year on year to ¥916 million and a swing to an operating loss of ¥98 million. Profit attributable to owners of the pa...
Taiko Pharmaceutical to Book HKD 15 Million Dividend from Asia-Pacific Subsidiary
Apr 24, 2026
Taiko Pharmaceutical Co., Ltd. will receive surplus dividends of HKD 15 million, about JPY 306 million, from its consolidated subsidiary Taiko Pharmaceutical (Asia Pacific) Co., Ltd., with receipt planned for May 25, 2026. The dividend will be boo...
Taiko Pharmaceutical Sets 2026 Deadline to Restore TSE Prime Listing Compliance
Mar 24, 2026
Taiko Pharmaceutical has fallen short of the Tokyo Stock Exchange Prime Market’s tradable share market capitalization requirement, with its freely traded share value at ¥9.0 billion at end-2025 versus the ¥10.0 billion threshold. T...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.